Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K
It is currently under clinical investigation for the management of obesity and type 2 diabetes (as demonstrated in a phase 2 trial published in the New England Journal of Medicine), and as of the time of writing, it has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Both Nu+Ex and Nu groups improved body cell mass and showed decreases in IL-6 and TNF-
For optimal glucose, and function combine ACG Gluco daily use with a healthy diet & exercise
The clinical dosage range spans 2.510 mg per subcutaneous injection, titrated over 4 weeks before reaching a maintenance dose of 510 mg, five times weekly